Malignant Minor Salivary Gland Carcinomas of the Larynx

Zhang, Ming; Li, Kenan; Li, Cai; Zhou, Liang; Zhu, Jiaxing; Wang, Shuyi

doi:10.1159/000368322

Cited by 14 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After isolating M0 patients without missing treatment information, we found that most minor salivary gland tumors were managed surgically (82.6%). Many of these tumors, such as adenoid cystic carcinomas, have a high propensity for submucosal, perineural, and lymphovascular spread, warranting extensive surgery, consistent with our findings on management practices . This is also consistent with a 1973 to 2011 SEER study, which demonstrated that surgery confers a significantly improved 5‐year survival compared to nonsurgical intervention (73.7% vs. 44.4%; P = 0.02) …”

Section: Discussionsupporting

confidence: 89%

Nonsquamous cell laryngeal cancers: Incidence, demographics, care patterns, and effect of surgery

et al. 2019

View full text Add to dashboard Cite

Objectives: To analyze the incidence and clinical profile of nonsquamous cell (non-SCC) laryngeal carcinomas and to analyze the effect of surgery on survival.Study Design: A retrospective analysis of the National Cancer Database (2004)(2005)(2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014).Methods: Adult patients with non-SCC laryngeal cancers were divided into six major histological subtypes. A descriptive clinical profile was obtained for non-SCC patients, and multivariate regressions were performed to analyze the effect of surgery on survival within the non-SCC cohort.Results: We identified 878 cases of non-SCC laryngeal cancers, representing 1.02% of all malignant laryngeal cancers. Neuroendocrine tumors and bone/cartilage sarcomas made up the largest groups (37.02% and 32.35%, respectively). Metastasis (M) was higher in neuroendocrine tumors, representing 19.1% of those with known clinical M stages. Of those treated, the majority of patients with bone/cartilage sarcomas (80.9%) and minor salivary gland tumors (82.6%) received surgery as part of their treatment. Survival varied significantly based upon histology, with bone/cartilage sarcomas having the highest 5-year survival at 90.4%, and neuroendocrine tumors exhibiting the poorest 5-year survival at 25.7%. Multivariate analyses found surgery to be significantly associated with improved survival (hazard ratio: 0.679; 95% confidence interval: 0.472-0.976; P = 0.036). The specific surgical method (i.e., local excision vs. partial vs. total laryngectomy) did not have any effect on survival.Conclusion: Approximately 1% of all malignant laryngeal cancers are non-SCC in origin. At presentation, neuroendocrine tumors have the highest rate of distant metastasis and have the worst prognosis of the non-SCC cancers. Most non-SCC patients received surgery as part of their treatment regimen.

show abstract

Section: Discussionsupporting

confidence: 89%

Nonsquamous cell laryngeal cancers: Incidence, demographics, care patterns, and effect of surgery

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Furthermore, 25 studies were identified through the reference lists of the retrieved articles and 1 of them was finally considered eligible for inclusion. Therefore, our scoping review consisted of 25 articles 12–36 . The flow chart of our scoping review is depicted in Figure 1.…”

Section: Resultsmentioning

confidence: 99%

Clinical Behavior of the Mucoepidermoid Carcinoma of the Larynx—A Scoping Review

Poutoglidis,

Forozidou,

Fyrmpas

et al. 2023

The Laryngoscope

View full text Add to dashboard Cite

ObjectiveMucoepidermoid carcinomas (MEC) of the larynx account for less than 1% of all laryngeal tumors. The unique features and clinical behavior of these rare entities remain unknown. To fill this knowledge gap, we performed a scoping review of every reported case of laryngeal MEC to study the clinical behavior and the treatment modalities in this rare entity.Review MethodsWe followed the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses extension for scoping reviews (PRISMA‐ScR) statement.Data SourcesMedLine, Google Scholar, and Science Direct databases were searched to identify eligible studies.ResultsWe concluded with 25 studies and overall 66 cases. Our study revealed that the average age of cases was 55.7 years, and the range was from 12 to 81 years, with younger onset in females. Supraglottic (60%) is the most common subsite of laryngeal MEC s followed by glottis (27.3%). Supraglottic carcinomas frequently present with metastatic neck disease at the time of the initial diagnosis and require more extensive surgical approaches. Surgery with negative surgical margins seems to be the cornerstone in the treatment of MEC. Radiation therapy has not been tested widely as monotherapy but is considered a useful adjuvant modality.ConclusionThis study suggests that negative surgical margins seem to be associated to higher disease control rate and that high‐grade supraglottic cases likely benefit from addressing neck disease simultaneously.Level of EvidenceNA Laryngoscope, 2023

show abstract

“…Conversely, tracheal localisation was dominated by ACC (99.5% of all tracheal cases) with only 1 MEC (0.5%). The TNM classification was reported in a few articles 2 , 3 , 10-19 ; in most cases tumours were advanced, while nodal involvement was rare. PNI was observed in 57.3% of patients and LVI was present in 39.4% (all had laryngeal MiSGC).…”

Section: Resultsmentioning

confidence: 99%

“…Minor salivary glands cancers (MiSGC) are found mostly in the oral cavity and oropharynx, while the larynx and trachea are seldom involved 1 . In particular, laryngeal MiSGC are extremely rare, accounting for less than 1% of all malignant tumors of this anatomical site 2 . The most common histotypes are adenoid cystic (ACC, 32-69%) and mucoepidermoid carcinomas (MEC, 15-35%) 3 .…”

Section: Introductionmentioning

confidence: 99%

Treatment and outcomes of minor salivary gland cancers of the larynx and trachea: a systematic review

Montenegro,

Mattavelli,

Lancini

et al. 2023

Acta Otorhinolaryngol Ital

View full text Add to dashboard Cite

SUMMARY Objectives Malignant minor salivary glands carcinomas (MiSGC) of the larynx and trachea are rare tumours and published evidence is sparse. We conducted a systematic review to describe shareable treatment strategies and oncological outcomes of these neoplastic entities. Methods Full text English manuscripts published from January 1 st 2000 to December 14 th 2022 were included. Data on demographics, treatments and outcomes were collected. A pooled analysis of 5-year overall survival (OS) was performed. Results Seventeen articles and 365 patients met the inclusion criteria. The most common subsites involved were subglottic and distal trachea. Adenoid cystic carcinoma was, by far, the most frequent histotype. The first-choice treatment strategy was surgery (86.8%), while adjuvant treatments were delivered in 57.4% of patients. Only 12.9% were treated with definitive radiotherapy with/without chemotherapy. The mean follow-up was 68.3 months. One hundred nine (34.9%) deaths were recorded and 62.4% were cancer-related. Five-year OS ranged from 20% to 100% and, at pooled analysis, it was 83% (range, 78-87%). Conclusions In case of MiSGC of the larynx and trachea, surgery remains the mainstay of treatment. Adjuvant treatments are frequently delivered. Survival estimates are good overall, but highly heterogeneous.

show abstract

Malignant Minor Salivary Gland Carcinomas of the Larynx

Cited by 14 publications

References 12 publications

Nonsquamous cell laryngeal cancers: Incidence, demographics, care patterns, and effect of surgery

Nonsquamous cell laryngeal cancers: Incidence, demographics, care patterns, and effect of surgery

Clinical Behavior of the Mucoepidermoid Carcinoma of the Larynx—A Scoping Review

Treatment and outcomes of minor salivary gland cancers of the larynx and trachea: a systematic review

Contact Info

Product

Resources

About